Collegium Pharmaceutical, Inc. beat EPS estimates 67% of the time across 12 reported quarters (8 beats, 4 misses), averaging +6.7% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $1.48 | $1.57 | +6.1% | Beat | Q2 FY26 call |
| Q1 FY26 | $1.23 | $1.50 | +21.9% | Beat | |
| Q4 FY25 | $2.01 | $1.85 | -8.0% | Miss | Q4 FY25 call |
| Q3 FY25 | $1.69 | $2.06 | +21.9% | Beat | |
| Q2 FY25 | $1.43 | $1.47 | +2.8% | Beat | |
| Q1 FY25 | $1.29 | $1.23 | -4.7% | Miss | |
| Q4 FY24 | $1.41 | $1.63 | +15.6% | Beat | |
| Q3 FY24 | $1.55 | $1.48 | -4.5% | Miss | |
| Q2 FY24 | $1.40 | $1.43 | +2.1% | Beat | |
| Q1 FY24 | $1.36 | $1.32 | -2.9% | Miss | |
| Q4 FY23 | $1.20 | $1.45 | +20.8% | Beat | |
| Q3 FY23 | $1.11 | $1.21 | +9.0% | Beat |
Back to COLL overview · COLL holders · COLL KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.